# Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia

> **NCT04683237** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **Xiaojun Chen**

## Conditions studied

- Atypical Endometrial Hyperplasia
- Obese
- Fertility Issues

## Interventions

- **DRUG:** Liraglutide Injection
- **DRUG:** Megestrol Acetate 160 MG

## Key facts

- **NCT ID:** NCT04683237
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-03-20
- **Primary completion:** 2025-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study.
- **Last updated:** 2024-09-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04683237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04683237, "Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04683237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*